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Plasma Adiponectin Levels and Sonographic Phenotypes of
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Data From the SAPHIR Study
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Background and Purpose—Adipose tissue produces and secretes a number of bioactive molecules, conceptualized as
adipocytokines. Adiponectin has been identified as one of the adipocytokines, and hypoadiponectinemia was
demonstrated in patients with obesity, diabetes mellitus, and coronary artery disease. Whether decreased adiponectin
levels are cause or consequence is an important issue in the discussion on the association between adiponectin and
atherosclerosis. In the present study, we investigated the association of plasma adiponectin levels with sonographic
phenotypes of subclinical atherosclerosis, which may represent different stages of disease as well as common and
distinct determinants.
Methods—A total of 1515 middle-aged healthy white subjects (940 males and 575 females) were included. Common
carotid artery intima-media thickness (CIMT) and presence of atherosclerotic plaques were assessed by B-mode
ultrasound.
Results—After adjustment for established risk factors, per 1 g/mL decrease in adiponectin CIMT increased on the average
by 3.48 m in males (95% CI, 1.23 to 5.73 m) and by 2.39 m in females (95% CI, 0.50 to 4.27 m). After
dichotomizing adiponectin levels at the median and adjustment for established risk factors, the mean difference of CIMT
between subjects with low and high adiponectin levels was 20.42 m in men (95% CI, 6.80 to 34.04; P0.003) and
20.75 m in women (95% CI, 1.08 to 40.42; P0.039). No significant relationship was found between adiponectin
levels and presence of atherosclerotic plaques.
Conclusion—Our results demonstrate an independent negative association of adiponectin levels and CIMT, whereas no
relationship with presence of atherosclerotic plaques was found, thus suggesting hypoadiponectinemia as a risk factor
in the development of early atherosclerosis. (Stroke. 2005;36:2577-2582.)
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Recent research has demonstrated that adipose tissueproduces and secretes a number of bioactive molecules,
conceptualized as adipocytokines, which may contribute to
the development of obesity-related diseases.1 Adiponectin2 is
an adipose-derived factor and suppresses various mechanisms
contributing to atherogenesis, including the expression of
adhesion molecules in endothelial cells,3,4 proliferation of
smooth muscle cells,5 and formation of foam cells in vitro.6
Physiological concentrations of adiponectin inhibit monocyte
adhesion to endothelial cells, transformation of macrophages
to foam cells and secretion of tumor necrosis factor- from
macrophages.3,4,6,7 Atheroprotective activity of adiponectin
was demonstrated in animal models,8 and hypoadiponectine-
mia was found in patients with obesity, type 2 diabetes
mellitus, and coronary artery disease (CAD).9,10 Weight
reduction increases adiponectin plasma concentrations.11 Hy-
poadiponectinemia 4 g/mL was associated with a 2-fold
increase in CAD prevalence in males, independent of estab-
lished risk factors.9 Adipocytes from type 2 diabetics are
resistant to insulin,12 suggesting reduced insulin sensitivity as
a reason of diminished adiponectin levels. Moreover, de-
creased adiponectin expression could reflect the dysfunc-
tional fat cell syndrome.13 These results suggest an associa-
tion between dysregulation of adipocytokines caused by
overnutrition and development of atherosclerosis. Whether
decreased adiponectin levels are cause or consequence in
atherogenesis has not been fully elucidated.14 In the present
study, we investigated the association of plasma adiponectin
levels with sonographic phenotypes of subclinical atheroscle-
rosis of the carotid arteries, which may represent different
stages of the disease as well as common and distinct
determinants.15
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The cohort of 1515 white subjects consisted of 940 males (40 to 55
years of ages) and 575 females (50 to 65 years of age) who are
participants of the Salzburg Atherosclerosis Prevention program in
subjects at High Individual Risk (SAPHIR). The study objectives,
recruitment procedures, and population characteristics have been
detailed.16,17 Subjects with clinical manifestations of atherosclerosis,
congestive heart failure, valvular heart disease, chronic alcohol (3
drinks per day) or drug abuse, morbid obesity (body mass index
[BMI] 40 kg/m2) were excluded to reduce possible confounding
from therapeutic interventions. Diabetes mellitus was defined by a
fasting glucose level of 7 mmol/L or antidiabetic treatment.
Twenty-four–hour ambulatory blood pressure measurement was
performed in all participants (TM 2430 PC system; BoschSohn).
Means of daytime (7 AM to 10 PM) measurements of systolic blood
pressure (SBP-d) were used in the analyses. Abdominal adipose
tissue areas were assessed by computed tomography (MX TWIN
Picker CT; Marconi Medical Systems) as described.18 Informed
consent was obtained from all participants, and the study was
approved by the local ethics committee.
Laboratory Data
Venous blood was collected after an overnight fast. Adiponectin was
measured using the human adiponectin ELISA kit (BioCat GmbH).
Total serum cholesterol, triglycerides, high-density lipoprotein cho-
lesterol (HDL), low-density lipoprotein cholesterol (LDL), high-
sensitive C-reactive protein (hs-CRP), fasting glucose, LDL size,
insulin sensitivity (k-ITT), and homeostasis model assessment
(HOMA) were determined as described.17
Ultrasonography
Carotid artery B-mode ultrasound measurements (ATL HDI 3000
CV; Philips Medical Systems) were performed and read by a single
experienced ultrasound operator blinded to clinical and laboratory
characteristics. The protocol included multiple longitudinal and
transverse imaging planes of the carotid arteries. Common carotid
artery intima-media thickness (CIMT) was measured end-diastolic
according to the leading edge method for the near and far walls,19
and mean values of left and right arteries were used in the statistical
analyses. The intraobserver variability of this method is low (3%
or 25 m).20 Atherosclerotic plaque was defined as a focal
structure encroaching into the arterial lumen of 0.5 mm or 50% of
the surrounding CIMT value or by a thickness of 1.5 mm as
measured from the media-adventitia interface to the intima-lumen
interface.21
Statistics
All analyses were performed using SPSS 12.0 package (SPSS Inc).
Characteristics of subjects are described as means and SDs (unless
otherwise indicated) and compared using t tests. Associations be-
tween adiponectin levels and various risk factors were measured by
Pearson correlation. The dependence of CIMT on the explanatory
variables was analyzed using general linear model (GLM), the
dependence of the presence or absence of atherosclerotic plaques on
the explanatory variables by logistic regression. The effect size Eta2
was used to analyze individual associations of the variables with
CIMT. GLM analysis was performed with adiponectin as a contin-
uous covariate as well as dichotomized (high/low) at the median. All
linear models were adjusted for age, blood pressure, LDL, BMI, and
smoking. For additional risk factors (HDL, LDL size, triglycerides,
diabetes mellitus, blood glucose, fasting insulin, HOMA index,
k-ITT, and hs-CRP), a forward stepwise procedure (P in 0.05; P
out 0.10) was used to choose those covariates that, in addition to
the aforementioned risk factors, had significant effects on
dependent variables.
Results
Tables 1, 2, and 3 summarize characteristics of the subjects
studied, correlations between plasma adiponectin levels and
TABLE 1. Clinical and Metabolic Characteristics of Subjects Studied
All (n1515) Males (n940) Females (n575)
P Value
(males vs females)Mean SD Mean SD Mean SD
CIMT, m 759.5 125.1 757.0 124.2 763.7 126.5 0.317
Adiponectin, g/mL 8.46 4.50 6.85 3.01 11.10 5.23 0.0005
Age, y 51.9 6.0 49.3 5.4 56.1 4.4 0.0005
BMI, kg/m2 26.7 3.9 27.0 3.5 26.3 4.5 0.004
Visceral fat, mm2 7750 4450 8200 4450 7010 4360 0.0005
Subcutaneous fat, mm2 19 980 9980 17 240 8230 24 530 1930 0.0005
SBP-d, mm Hg 133.6 12.9 135.1 12.5 131.2 13.3 0.0005
DBP-d, mm Hg 82.0 7.9 82.5 8.0 81.1 7.6 0.001
LDL, mmol/L 3.77 0.94 3.78 0.93 3.72 0.96 0.185
HDL, mmol/L 1.54 0.40 1.41 0.34 1.75 0.42 0.0005
Total cholesterol, mmol/L 5.92 1.04 5.86 1.03 6.01 1.04 0.007
Triglycerides, mmol/L 1.43 0.99 1.58 1.15 1.18 0.58 0.0005
Fasting glucose, mmol/L 5.21 1.02 5.27 1.04 5.1 0.97 0.004
Fasting Insulin, U/mL 7.48 5.11 7.74 5.65 7.06 4.05 0.007
k-ITT 4.15 1.31 4.10 1.38 4.24 1.20 0.038
HOMA 1.81 1.54 1.88 1.60 1.70 1.43 0.021
hs-CRP, mg/L 2.90 6.57 2.63 7.44 3.35 4.79 0.037
LDL size, nm 266.5 11.2 264.1 11.8 270.3 9.1 0.0005
Smoking, yes (%) 503 (33.2%) 365 (38.8%) 138 (24.0%) 0.0005
Diabetes mellitus, yes (%) 61 (4.0%) 42 (4.5%) 19 (3.3%) 0.116
K-ITT indicates the short insulin tolerance test.
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metabolic parameters, and correlations of CIMT with tradi-
tional risk factors. A significant sex difference was observed
for adiponectin levels 4 g/mL, which were found in 135
(14.4%) men but only in 20(3.5%) women (P0.0005). GLM
analysis was performed with age, blood pressure (SBP-d),
LDL, BMI, and smoking as main effects, demonstrating a
significant negative association between adiponectin levels
and CIMT (P0.004). Because significant (P0.05) interac-
tion effects with sex were found for LDL, smoking, and age,
males and females were subsequently analyzed separately,
with age, SBP, LDL, BMI, and smoking in the linear model
alongside adiponectin. For males, all variables showed sig-
nificant impact on CIMT, including adiponectin with
P0.032. For females only, age, SBP-d, and adiponectin with
P0.047 were significant (Table 4). Because of the strong
correlation between body fat and adiponectin, supplementary
analysis was performed without adjustment for BMI, yielding
the expected stronger impact of adiponectin (Table 5). Ex-
tending GLM analysis by the stepwise procedure described
above yielded the following results. In males, hs-CRP had
significant impact on CIMT, whereas diabetes mellitus and
LDL size proved significant for females. After including
these variables in the model, the adiponectin effect remained
significant in males (P0.040) but not in females (P0.114).
For males, per 1 g/mL decrease of adiponectin, CIMT
increased on the average by 3.48 m (95% CI, 1.23 to
5.73 m). For females, a decrease of 1 g/mL adiponectin
increased CIMT on average by 2.39 m (95% CI, 0.50 to
4.27 m). Using the dichotomized adiponectin level (above/
below the median [750 m]) as explanatory variable and
adjustment for age, SBP, LDL cholesterol, BMI, and smok-
ing, the mean difference of CIMT between subjects with low
and such with high adiponectin levels was 15.61 m in men
(SE 7.05; P0.027; 95% CI, 1.77 to 29.45) and 17.02 m in
women (SE 10.21; P0.096; 95% CI, 3.03 to 37.07).
Removing BMI from the model resulted in a pronounced
adiponectin effect: Mean CIMT difference increased to
20.42 m in men (SE 6.94; P0.003; 95% CI, 6.80 to 34.04)
and to 20.75 m in women (SE 10.01; P0.039; 95% CI,
1.08 to 40.42). The Figure shows 95% CIs for mean adjusted
CIMT (at 53 years of age; SBP 133 mm Hg and LDL
3.8 mmol/L) by adiponectin dichotomized at the median.
Atherosclerotic plaques were observed in 355 (23.4%)
subjects (209 men [22.2%], 146 women [25.4%], NS). For
investigation of the association of adiponectin with athero-
sclerotic plaques, logistic regression analysis with the above-
mentioned explanatory variables was performed. Age, blood
pressure (SBP-d), LDL, and triglycerides were significant
predictors in males, whereas age, LDL, smoking, and diabe-
tes proved significant in females. Adiponectin was far from
significance in males and females.
Discussion
To our best knowledge, this is the first study demonstrating
an association of adiponectin levels and CIMT in a large
population, thus confirming similar observations in a limited
cohort.22 An important issue in the discussion on the associ-
ation between adiponectin and atherosclerosis is whether the
decreased adiponectin levels are cause or consequence. Pu-
tative mechanisms include reduced production in adipocytes
as a marker of the dysfunctional fat cell syndrome,13 in-
creased consumption in the blood stream, or a combination of
both.14 This is of particular interest considering the growing
evidence suggesting that different ultrasound determinations
of carotid atherosclerosis may represent different stages of
disease as well as distinct and common determinants.15
Among carotid ultrasound parameters, CIMT probably re-













Fasting insulin r 0.316 0.323 0.210 0.278 0.291 0.179
k-ITT r 0.237 0.243 0.161 0.222 0.240 0.153
HOMA r 0.257 0.262 0.149 0.240 0.251 0.141
LDL size r 0.284 0.286 0.243 0.275 0.276 0.243
HDL r 0.344 0.344 0.281 0.425 0.424 0.360
TG r 0.250 0.251 0.185 0.227 0.235 0.182
All correlations were significant, with P0.0005 with the exception for HOMA adjusted for age and BMI in females
with P0.001.
r indicates correlation coefficient (Pearson); TG, triglycerides; k-ITT, the short insulin tolerance test.
TABLE 3. Correlation Between CIMT and Established Risk
Factors (unadjusted)
Pearson All Males Females
Adiponectin r 0.065 0.092 0.086
P value 0.012 0.005 0.039
Age r 0.360 0.478 0.290
P value 0.0005 0.0005 0.0005
BMI r 0.205 0.253 0.152
P value 0.0005 0.0005 0.0005
LDL r 0.128 0.186 0.039
P value 0.0005 0.0005 0.352
SBP-d r 0.218 0.233 0.211
P value 0.0005 0.0005 0.0005
Smoking r 0.017 0.077 0.081
P value 0.516 0.019 0.051
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flects earlier stages of atherogenesis, notably a hypertrophic
response of intimal and medial cells to lipid infiltration and
hypertension.15 Furthermore, modest to moderate associa-
tions of CIMT with various cerebrovascular and cardiovas-
cular end points have established CIMT as a surrogate
parameter of clinical end points.23–25 Adiponectin suppresses
various mechanisms contributing to atherogenesis,5,6,26,27 and
our results are consistent with this background. In contrast,
our data do not support the mechanism of hypoadiponectine-
mia caused by accumulation in the injured artery wall7
because we found no significant association between de-
creased adiponectin levels and atherosclerotic plaque.
Previously described associations of adiponectin levels and
various markers for progression of atherosclerosis (insulin-
resistant state28,29 and atherogenic lipoprotein profile29,30) are
confirmed by our findings (Table 2).
The sex differences of plasma adiponectin concentrations
in our population remained significant after adjustment for
parameters of body fat (BMI and visceral and subcutaneous
adipose tissue) and may be explained by the higher amount of
visceral fat in men. A sex-based difference of adiponectin
levels is supported by some30,31 but not all other studies.28
Animal and in vitro models suggest androgen-induced hypoa-
diponectinemia as connecting link between visceral fat,
insulin resistance, and atherosclerosis in men,30,31 whereas
other studies reported similar adiponectin concentrations for
men and women with comparable amounts of liver fat, which
were clearly associated with visceral fat mass.32 The stronger
impact of adiponectin on CIMT in men is consistent with data
reporting an association of low adiponectin, CAD, and
atherosclerosis almost exclusively in male populations.9,33,34
This finding may be explained by the significantly higher
TABLE 4. GLM Analysis for CIMT on Age, SBP, LDL, BMI, Smoking, and Adiponectin
Trait Coefficient B SE(B) P Value
95% CI
Eta2Low High
Males Age 9.84 0.64 0.0005 8.58 11.10 0.201
SBP 1.35 0.29 0.0005 0.78 1.92 0.023
R 20.295 LDL 0.432 0.096 0.0005 0.244 0.620 0.021
R 2 adjusted0.291 BMI 3.44 1.08 0.001 1.32 5.55 0.011
Smoking 12.81* 7.07 0.070 1.07 26.68 0.004
Adiponectin 2.53 1.18 0.032 4.85 0.22 0.005
Females Age 7.60 1.18 0.0005 5.291 9.913 0.068
SBP 1.33 0.39 0.001 0.56 2.10 0.020
R 20.127 LDL 0.072 0.134 0.592 0.191 0.335 0.001
R 2 adjusted0.118 BMI 1.92 1.21 0.111 0.446 4.293 0.004
Smoking 10.52* 11.79 0.373 12.636 33.667 0.001
Adiponectin 1.98 0.99 0.047 3.922 0.029 0.007
*The mean difference in CIMT between smokers and exsmokers and nonsmokers/pipe smokers, adjusted for the
other covariates in the model.
R 2 indicates coefficient of determination of the whole model; R 2 adjusted, coefficient of determination adjusted for
the No. of parameters in the whole model.
TABLE 5. GLM Analysis for CIMT on Age, SBP, LDL, Smoking and Adiponectin
Trait Coefficient B SE(B) P Value
95% CI
Eta2Low High
Males Age 10.17 0.64 0.0005 8.91 11.42 0.214
SBP 1.64 0.28 0.0005 1.10 2.19 0.036
R 2 adjusted0.284 LDL 0.449 0.096 0.0005 0.260 0.638 0.023
R 20.288 Smoking 14.41* 7.09 0.042 0.51 28.32 0.004
Adiponectin 3.48 1.15 0.002 5.73 1.23 0.010
Females Age 7.69 1.18 0.0005 5.38 10.00 0.070
SBP 1.50 0.38 0.0005 0.75 2.24 0.027
R 20.123 LDL 0.084 0.134 0.530 0.179 0.347 0.001
R 2 adjusted0.115 Smoking 11.27* 11.79 0.340 34.44 11.89 0.002
Adiponectin 2.39 0.96 0.013 4.27 0.50 0.011
*The mean difference in CIMT between smokers and exsmokers and nonsmokers/pipe smokers, adjusted for the
other covariates in the model.
R 2 indicates coefficient of determination of the whole model; R 2 adjusted, coefficient of determination adjusted for
the No. of parameters in the whole model.
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number of men with an adiponectin level 4 g/mL, which
was demonstrated to be associated with an increased risk for
CAD prevalence,9 thus suggesting a threshold value for the
atheroprotective effect of adiponectin. The main determinants
of CIMT are age and SBP,15 and the impact of all other risk
factors on CIMT is comparatively weak. The effect size of
low adiponectin levels on CIMT is stronger than that of
smoking in both sexes and stronger than the effect of LDL
cholesterol in females. Thus, the results of our analyses
strongly suggest low adiponectin as a risk factor for early
atherosclerosis as reflected by CIMT. This effect is indepen-
dent from the abovementioned relationships to obesity, glu-
cose, and lipid metabolism. However, the cross-sectional
design of our study warrants cautious interpretation of results,
and further investigations are necessary to substantiate these
findings.
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